Getinge AB (publ) (GNGBF)
| Market Cap | 5.58B +5.9% |
| Revenue (ttm) | 3.58B -4.1% |
| Net Income | 247.88M +59.5% |
| EPS | 0.91 +59.5% |
| Shares Out | n/a |
| PE Ratio | 22.52 |
| Forward PE | 15.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152 |
| Average Volume | 1,577 |
| Open | 23.23 |
| Previous Close | 24.75 |
| Day's Range | 23.23 - 23.23 |
| 52-Week Range | 18.82 - 24.75 |
| Beta | 0.86 |
| RSI | 58.35 |
| Earnings Date | Apr 21, 2026 |
About Getinge AB
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardioth... [Read more]
Financial Performance
In 2025, Getinge AB's revenue was 34.97 billion, an increase of 0.60% compared to the previous year's 34.76 billion. Earnings were 2.26 billion, an increase of 37.85%.
Financial numbers in SEK Financial StatementsNews
Getinge AB (GNGBY) Q1 2026 Earnings Call Highlights: Navigating Currency Headwinds and ...
Getinge AB (GNGBY) Q1 2026 Earnings Call Highlights: Navigating Currency Headwinds and Sustaining Growth
Getinge maintains FY26 organic sales growth view of 3%-5%
There is currently high geopolitical uncertainty, however, based on dialogue with its customers Getinge (GNGBY) is maintaining the forecast of organic sales growth of 3-5% in 2026. Published first on…
Getinge AB Earnings Call Transcript: Q1 2026
Organic net sales grew 0.8% year-over-year, with strong order intake and solid cash flow despite SEK 226 million in tariff and currency headwinds. Life Science and Surgical Workflows led growth, while guidance for 2026 organic net sales growth of 3%-5% was reiterated.
Getinge AB Earnings Call Transcript: Q4 2025
Record organic sales growth in Q4 2025 was driven by strong performance in Acute Care Therapies and Surgical Workflows, while Life Science lagged. Margin expansion remains a focus for 2026 despite ongoing tariff and FX headwinds, with 3%-5% organic net sales growth guided.
Getinge upgraded to Buy from Hold at Nordea
Nordea analyst Ludvig Lundgren upgraded Getinge (GNGBY) to Buy from Hold with a SEK 245 price target
Getinge downgraded to Hold from Buy at Pareto
Pareto downgraded Getinge (GNGBY) to Hold from Buy with a SEK 245 price target
Getinge AB Earnings Call Transcript: Q3 2025
Strong organic growth and margin improvement in Q3 2025, with robust performance in Acute Care Therapies and Life Science. Tariffs and FX remain headwinds, but guidance for 2–5% organic net sales growth and long-term EPS targets are maintained.
Medical gear maker Getinge tops core profit estimates in third quarter
Swedish medical equipment maker Getinge reported third-quarter core earnings above market expectations on Tuesday, supported by price adjustments to combat a hit from U.S. tariffs and negative currenc...
Getinge price target lowered to SEK 175 from SEK 182 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Getinge (GNGBY) to SEK 175 from SEK 182 and keeps an Equal Weight rating on the shares.
Getinge price target lowered to SEK 165 from SEK 191 at JPMorgan
JPMorgan lowered the firm’s price target on Getinge (GNGBY) to SEK 165 from SEK 191 and keeps an Underweight rating on the shares.
Getinge AB Earnings Call Transcript: Q2 2025
Solid organic growth and margin improvement achieved despite significant tariff and FX headwinds, with strong performance in Acute Care Therapies and Surgical Workflows. Financial position remains robust, and 2025 guidance for 2–5% organic net sales growth is reaffirmed.
Getinge price target lowered to SEK 182 from SEK 191 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Getinge (GNGBY) to SEK 182 from SEK 191 and keeps an Equal Weight rating on the shares.
Getinge initiated with a Market Perform at Bernstein
Bernstein analyst Delphine Le Louet initiated coverage of Getinge (GNGBY) with a Market Perform rating and SEK 228 price target The firm notes Getinge is a global leader in hospital…
Getinge price target lowered to SEK 191 from SEK 197 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Getinge (GNGBY) to SEK 191 from SEK 197 and keeps an Equal Weight rating on the shares.
Getinge AB Earnings Call Transcript: Q1 2025
Order intake rose 7.1% and net sales grew 10.7% year-over-year, led by acute care therapies and Americas. Margins improved despite FX headwinds, and leverage remains stable post-acquisition. 2025 outlook is for 2–5% organic sales growth, with ongoing market and tariff uncertainties.
Getinge Interim Report January-March 2025: Strong sales and improved earnings - continued focus on customer value and profitability going forward
GOTHENBURG, Sweden , April 22, 2025 /PRNewswire/ -- "We are entering 2025 with healthy organic sales growth and improved adjusted operating profit despite headwinds from currency effects," says Mattia...
Getinge upgraded to Outperform from Market Perform at Handelsbanken
Handelsbanken analyst Rickard Anderkrans upgraded Getinge (GNGBY) to Outperform from Market Perform with a SEK 300 price target
Getinge price target raised to SEK 197 from SEK 187 at Morgan Stanley
Morgan Stanley analyst Robert Davies raised the firm’s price target on Getinge (GNGBY) to SEK 197 from SEK 187 and keeps an Equal Weight rating on the shares. Published first…
Getinge price target raised to SEK 191 from SEK 160 at JPMorgan
JPMorgan raised the firm’s price target on Getinge (GNGBY) to SEK 191 from SEK 160 and keeps an Underweight rating on the shares.
Getinge downgraded to Market Perform from Outperform at Handelsbanken
Handelsbanken downgraded Getinge (GNGBY) to Market Perform from Outperform with a price target of SEK 300, up from SEK 275.
Getinge AB Earnings Call Transcript: Q4 2024
Q4 delivered strong organic growth in orders and sales, with significant margin improvement and robust free cash flow. The phase-out of Surgical Perfusion and Paragonix acquisition were key events, while quality costs peaked but are expected to decline.
Getinge upgraded to Hold from Sell at Nordea
Nordea analyst David Johansson upgraded Getinge (GNGBY) to Hold from Sell saying competitive concerns are peaking.
Getinge price target lowered to SEK 160 from SEK 180 at JPMorgan
JPMorgan lowered the firm’s price target on Getinge (GNGBY) to SEK 160 from SEK 180 and keeps an Underweight rating on the shares.
Getinge price target lowered to SEK 180 from SEK 190 at JPMorgan
JPMorgan lowered the firm’s price target on Getinge (GNGBY) to SEK 180 from SEK 190 and keeps an Underweight rating on the shares.
Getinge downgraded to Sell from Hold at Nordea
Nordea downgraded Getinge (GNGBY) to Sell from Hold with an SEK 180 price target